High materiality7/10
Nurix Therapeutics price target lowered to $33 from $34 at Truist
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist trimmed NRIX target to $33 from $34; current price $22.40. Target still implies upside.
- Truist trims NRIX target to $33; current price $22.40.
Key facts
- 01
Target: $33
- 02
Posted price: $22.4
- 03
Analyst firm: Truist Financial
- 04
Analyst: Gregory Renza
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.